Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 21
Filter
1.
Oncogene ; 26(33): 4863-71, 2007 Jul 19.
Article in English | MEDLINE | ID: mdl-17297445

ABSTRACT

Loss of JunB has been observed in human leukemia and lymphoma, but it remains unknown, whether this loss is relevant to disease progression. Here, we investigated the consequences of JunB deficiency using Abelson-induced B-lymphoid leukemia as a model system. Mice deficient in JunB expression succumbed to Abelson-induced leukemia with increased incidence and significantly reduced latency. Similarly, bcr/abl p185-transformed JunB-deficient (junB(Delta/Delta)) cells induced leukemia in RAG2(-/-) mice displaying a more malignant phenotype. These observations indicated that cell intrinsic effects within the junB(Delta/Delta) tumor cells accounted for the accelerated leukemia development. Indeed, explantated bcr/abl p185 transformed junB(Delta/Delta) cells proliferated faster than the control cells. The proliferative advantage emerged slowly after the initial transformation process and was associated with increased expression levels of the cell cycle kinase cdk6 and with decreased levels of the cell cycle inhibitor p16(INK4a). These alterations were due to irreversible reprogramming of the cell, because - once established - accelerated disease induced by junB(Delta/Delta) cells was not reverted by re-introducing JunB. Consistent with this observation, we found that the p16 promoter was methylated. Thus, JunB functions as a gatekeeper during tumor evolution. In its absence, transformed leukemic cells acquire an enhanced proliferative capacity, which presages a more malignant disease.


Subject(s)
Leukemia, Lymphoid/pathology , Proto-Oncogene Proteins c-jun/physiology , Animals , Blotting, Western , Cell Line , Cell Line, Tumor , Cell Proliferation , Cell Survival , Cells, Cultured , Cyclin-Dependent Kinase 6/genetics , Cyclin-Dependent Kinase 6/metabolism , Cyclin-Dependent Kinase Inhibitor p16/genetics , Cyclin-Dependent Kinase Inhibitor p16/metabolism , DNA-Binding Proteins/genetics , DNA-Binding Proteins/metabolism , DNA-Binding Proteins/physiology , Flow Cytometry , Fusion Proteins, bcr-abl/genetics , Fusion Proteins, bcr-abl/metabolism , Fusion Proteins, bcr-abl/physiology , Gene Expression , Green Fluorescent Proteins/genetics , Green Fluorescent Proteins/metabolism , Leukemia, Experimental/genetics , Leukemia, Experimental/metabolism , Leukemia, Experimental/pathology , Leukemia, Lymphoid/genetics , Leukemia, Lymphoid/metabolism , Mice , Mice, Inbred C57BL , Mice, Knockout , Mice, Nude , Proto-Oncogene Proteins c-jun/genetics , Proto-Oncogene Proteins c-jun/metabolism , Reverse Transcriptase Polymerase Chain Reaction , Time Factors , Transfection
2.
Ann Oncol ; 13(6): 965-73, 2002 Jun.
Article in English | MEDLINE | ID: mdl-12123343

ABSTRACT

BACKGROUND: Although fatigue is a commonly reported symptom in cancer patients its etiology is still poorly understood. The objective of the present study was to investigate the relationship between hemoglobin (Hb) levels and the subjective experience of fatigue and quality of life in cancer patients with mild or no anemia undergoing chemotherapy. PATIENTS AND METHODS: Sixty-eight cancer patients (25 colorectal, 26 lung and 17 ovarian cancer) presently undergoing chemotherapy participated in the study. Fatigue was measured with the Multidimesional Fatigue Inventory (MFI-20), quality of life with The European Organization for Research and Treatment of Cancer QLQ-C30. In order to provide normative data for fatigue levels, the MFI-20 was also completed by a sex- and age-matched sample of 120 healthy controls. RESULTS: Compared with healthy subjects, cancer patients experienced significantly higher levels of subjective fatigue. Correlations between Hb values and subscales of the MFI-20 were moderate with a tendency to increase during chemotherapy. Hb values alone, however, do not fully account for the observed fatigue. Other symptoms, especially pain, dyspnea and sleep disturbances, also showed an association with perceived fatigue. CONCLUSIONS: Despite significant correlations, these results indicate that Hb values only partially explain subjectively experienced fatigue and quality of life in cancer patients. It is suggested therefore that the treatment of fatigue must be multidimensional and involve all areas which contribute to the syndrome.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/adverse effects , Fatigue/diagnosis , Hemoglobins/analysis , Neoplasms/drug therapy , Neoplasms/psychology , Quality of Life , Adult , Aged , Anemia/diagnosis , Anemia/etiology , Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Case-Control Studies , Cohort Studies , Colorectal Neoplasms/drug therapy , Colorectal Neoplasms/physiopathology , Colorectal Neoplasms/psychology , Fatigue/etiology , Female , Humans , Lung Neoplasms/drug therapy , Lung Neoplasms/physiopathology , Lung Neoplasms/psychology , Male , Middle Aged , Neoplasms/physiopathology , Ovarian Neoplasms/drug therapy , Ovarian Neoplasms/physiopathology , Ovarian Neoplasms/psychology , Probability , Prognosis , Reference Values , Sensitivity and Specificity , Severity of Illness Index , Surveys and Questionnaires
3.
Adv Exp Med Biol ; 457: 141-50, 1999.
Article in English | MEDLINE | ID: mdl-10500789

ABSTRACT

To determine the clinical significance of the multidrug resistance protein (MRP) in patients with de novo AML, we have studied MRP expression of leukemic cells at diagnosis and its association with clinical outcome in 127 patients. MRP expression was determined by immunocytochemistry by means of monoclonal antibodies QCRL-1/QCRL-3. MRP expression was low, intermediate and high in 30%, 46% and 24% of the patients, respectively. MRP expression was independent of age and sex of the patients, white blood cell count, FAB subtype, serum lactate dehydrogenase levels and karyotype aberrations. MRP expression had no impact no response to induction chemotherapy. The complete remission rates were 75%, 70% and 64% for patients with low, intermediate and high expression, respectively. Patients with intermediate or high MRP expression showed a trend toward shorter overall survival (p = 0.09) as compared to patients with low MRP expression. MRP does not predict for response to induction chemotherapy but intermediate or high MRP expression might be associated with shorter overall survival of the patients.


Subject(s)
ATP Binding Cassette Transporter, Subfamily B, Member 1/genetics , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Drug Resistance, Multiple , Leukemia, Myeloid, Acute/drug therapy , ATP Binding Cassette Transporter, Subfamily B, Member 1/analysis , Adolescent , Adult , Aged , Aged, 80 and over , Disease-Free Survival , Female , Humans , Karyotyping , Leukemia, Myeloid, Acute/genetics , Leukemia, Myeloid, Acute/mortality , Leukemia, Myeloid, Acute/pathology , Male , Middle Aged , Remission Induction , Survival Rate
4.
Wien Klin Wochenschr ; 109(17): 688-91, 1997 Sep 19.
Article in English | MEDLINE | ID: mdl-9331958

ABSTRACT

Gemcitabine has shown activity in different solid tumors. In the present study we have evaluated its efficacy in 32 patients with advanced non-small-cell lung cancer in a phase II trial. Gemcitabine (1250 mg/m2) was given intravenously as a 30-minute infusion on days 1, 8 and 15. Cycles were repeated every 4 weeks. Twenty-nine patients were evaluable for response and all patients for toxicity. Partial remissions and stable disease were seen in 4 (14%) and 13 (45%) patients, respectively. Improvement of symptoms occurred in 54% of the patients. Side effects were mild and included predominantly leukopenia and thrombocytopenia. In conclusion, gemcitabine is active and well tolerated in patients with advanced non-small-cell lung cancer.


Subject(s)
Antimetabolites, Antineoplastic/administration & dosage , Carcinoma, Non-Small-Cell Lung/drug therapy , Deoxycytidine/analogs & derivatives , Lung Neoplasms/drug therapy , Adult , Aged , Aged, 80 and over , Antimetabolites, Antineoplastic/adverse effects , Austria , Carcinoma, Non-Small-Cell Lung/pathology , Deoxycytidine/administration & dosage , Deoxycytidine/adverse effects , Dose-Response Relationship, Drug , Drug Administration Schedule , Female , Humans , Infusions, Intravenous , Lung Neoplasms/pathology , Male , Middle Aged , Neoplasm Staging , Palliative Care , Treatment Outcome , Gemcitabine
5.
Eur J Cancer ; 33(9): 1516-8, 1997 Aug.
Article in English | MEDLINE | ID: mdl-9337699

ABSTRACT

Because P-glycoprotein expression might be associated with a more aggressive behaviour of colorectal carcinomas (Weinstein et al., Cancer Res, 1991, 51, 2720-2726), we determined the relationship between MDR1 RNA expression of the carcinomas and the survival of the patients. At a median duration of follow-up of 86 months, event-free survival of patients with MDR1 RNA-negative tumours (n = 35) was not significantly different to that of patients with MDR1 RNA positive tumours (n = 67). Among the different tumour stages, event-free survival of the patients was also independent of MDR1 gene expression of the tumours. Thus, these findings do not support the hypothesis that local aggressiveness of P-glycoprotein positive tumour cells translates into worse clinical outcome.


Subject(s)
ATP Binding Cassette Transporter, Subfamily B, Member 1/metabolism , Biomarkers, Tumor/metabolism , Colorectal Neoplasms/metabolism , Neoplasm Proteins/metabolism , ATP Binding Cassette Transporter, Subfamily B, Member 1/genetics , Biomarkers, Tumor/genetics , Colorectal Neoplasms/genetics , Follow-Up Studies , Gene Expression , Genes, MDR , Humans , Neoplasm Proteins/genetics , Prognosis , RNA, Neoplasm/genetics , Survival Rate
6.
Clin Cancer Res ; 3(8): 1419-25, 1997 Aug.
Article in English | MEDLINE | ID: mdl-9815827

ABSTRACT

Drug resistance remains a major problem in the treatment of patients with acute myeloid leukemia (AML). Expression of the MDR1 gene in leukemic cells was shown previously to be associated with worse clinical outcome of the patients. The multidrug resistance-associated protein (MRP) has been shown recently to be another protein causing the multidrug resistance phenotype in cell lines, but its impact on clinical outcome in patients with AML remains to be proven. To determine the clinical significance of MRP in patients with de novo AML, we have studied the MRP expression in leukemic cells and its association with both response to induction chemotherapy and survival of the patients. MRP gene expression was determined by immuno-cytochemistry (n = 80) by means of the monoclonal antibodies QCRL-1 and QCRL-3. MRP expression was low, intermediate, and high in 19, 55, and 26% of the patients, respectively. High MRP expression was independent of age and sex of the patients, WBC count, and percentage of blasts. However, high MRP expression was more frequent in the FAB M5 subtype as compared to the other subtypes. MRP expression had no impact on clinical outcome. The complete remission rates were 65, 68, and 63% for patients with low, intermediate, and high expression, respectively. Overall survival was also independent of MRP expression. In contrast, patients with P-glycoprotein-positive AML had lower complete remission rates and shorter durations of survival. These data indicate that MRP is expressed in patients with de novo AML but, in contrast to P-glycoprotein, does not predict for outcome of induction chemotherapy or survival.


Subject(s)
ATP Binding Cassette Transporter, Subfamily B, Member 1/genetics , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Drug Resistance, Multiple/genetics , Leukemia, Myeloid/drug therapy , Leukemia, Myeloid/genetics , ATP Binding Cassette Transporter, Subfamily B, Member 1/analysis , Acute Disease , Adolescent , Adult , Aged , Aged, 80 and over , Bone Marrow/pathology , Cell Line , Cytarabine/administration & dosage , Daunorubicin/administration & dosage , Disease-Free Survival , Etoposide/administration & dosage , Female , Humans , Karyotyping , Leukemia, Myeloid/mortality , Leukemia, Myeloid/pathology , Male , Middle Aged , Prognosis , Remission Induction , Survival Analysis , Time Factors , Treatment Outcome , Tumor Cells, Cultured
7.
Leukemia ; 11(5): 639-43, 1997 May.
Article in English | MEDLINE | ID: mdl-9180285

ABSTRACT

We examined the presence of WT1-specific mRNA in bone marrow samples of 125 patients with de novo acute myeloid leukemia at diagnosis by two-step RT-PCR. The sensitivity of the assay was 1:100 (first step) and 1:10000 (second step), respectively. WT1-specific mRNA was detected in 73% of patients. No correlation was found between WT1 gene expression and age, FAB type, LDH and karyotype at diagnosis. All patients were treated with standard induction chemotherapy. There was no difference in the CR rate between WT1-positive and -negative patients. Using Kaplan and Meier plot analysis we found no difference in disease-free survival (DFS) and overall survival (OS) between patients displaying the WT1 transcript and WT1-negative patients. Furthermore, no significant interactions between WT1 PCR results and age, FAB type, LDH and karyotype on DFS and OS were demonstrable using Cox regression analysis. Eight patients who were WT1 PCR positive at diagnosis and achieved complete hematological remission following chemotherapy were monitored during the course of the disease. Based on our limited data demonstrating a heterogeneity of WT1 PCR results in CR we cannot draw any conclusions regarding the usefulness of WT1 PCR analysis for the early detection of relapse. We conclude that WT1 gene expression at diagnosis is not associated with specific characteristics of AML blast cells and is not a prognostic factor for CR, remission duration and overall survival in acute myeloid leukemia.


Subject(s)
DNA-Binding Proteins/biosynthesis , Genes, Wilms Tumor , Leukemia, Myeloid/drug therapy , Leukemia, Myeloid/genetics , Transcription Factors/biosynthesis , Transcription, Genetic , Acute Disease , Adolescent , Adult , Aged , Aged, 80 and over , Bone Marrow/pathology , Disease-Free Survival , Female , Humans , Karyotyping , Leukemia, Myeloid/mortality , Leukemia, Myeloid/pathology , Male , Middle Aged , Polymerase Chain Reaction , Predictive Value of Tests , Probability , Prognosis , RNA, Messenger/biosynthesis , Sensitivity and Specificity , Survival Rate , Time Factors , WT1 Proteins
8.
Anticancer Res ; 17(1B): 749-52, 1997.
Article in English | MEDLINE | ID: mdl-9066614

ABSTRACT

The MDR1 gene is of prognostic significance in acute myeloid leukemia (AML). The relationship of this gene to surface markers largely remains unclear. Therefore, we have studied the association of MDR1 gene expression with the expression of specific surface markers in AML. MDR1 RNA expression of leukemic cells was determined by slot blot analysis. Expression of P-glycoprotein and surface markers (CD7, CD13, CD19, CD34, HLA-DR, TdT, blood group H) was assessed by immunocytochemistry. MDR1 RNA (n = 79) and P-glycoprotein (n = 52) expression were detected in 63% and 63% of the patients, respectively. CD7, CD13, CD19, CD34, HLA-DR, TdT and blood group H were positive in 17%, 84%, 0%, 51%, 82%, 11% and 11% of the patients. MDR1 RNA or P-glycoprotein expression were not associated with the expression of either CD7, CD13, CD19, CD34, TdT or blood group H. However, P-glycoprotein expression was more frequent in HLA-DR positive than in HLA-DR negative patients (47% versus 10%, p = 0,04). Consistent with the latter finding, patients with intermediate or high MDR1 RNA expression expressed HLA-DR more frequently than patients with negative or weak MDR1 RNA expression (96% versus 76%, p = 0,03). In conclusion, MDR1 gene expression of AML cells was independent of surface markers except HLA-DR.


Subject(s)
ATP Binding Cassette Transporter, Subfamily B, Member 1/metabolism , Antigens, Neoplasm/metabolism , Antigens, Surface/metabolism , Gene Expression Regulation, Leukemic , Genes, MDR/physiology , Leukemia, Myeloid/metabolism , ATP Binding Cassette Transporter, Subfamily B, Member 1/genetics , Acute Disease , Female , Humans , Leukemia, Myeloid/immunology , Male , RNA, Messenger/metabolism
10.
Leuk Lymphoma ; 23(5-6): 451-8, 1996 Nov.
Article in English | MEDLINE | ID: mdl-9031075

ABSTRACT

Drug resistance often results in failure of anticancer chemotherapy in leukemias. Several mechanisms of drug resistance are known with multidrug resistance (MDR) being the best characterized one. MDR can be due to enhanced expression of certain genes (MDR1, MRP or LRP), alterations in glutathione-S-transferase activity or GSH levels and to reduction of the amount or the activity of topoisomerase II. Here we review the current status of the clinical significance of the various mechanisms of MDR in leukemias and also discuss possibilities for the reversal of MDR. MDR1 gene expression has been seen in many leukemias, notably in acute myeloid leukemia (AML) and blast crisis of chronic myeloid leukemia. Both MDR1 RNA and P-glycoprotein expression of the leukemic cells have been shown to correlate with poor clinical outcome in AML. However, preliminary results indicate that the MRP gene as well as the LRP gene can be expressed in AML. Thus, drug resistance in leukemias appears to be multifactorial. P-glycoprotein-mediated MDR can be reversed by several drugs. These resistance modifiers are currently evaluated with regard to their clinical efficacy. Despite some encouraging results, reversal of drug resistance and subsequent improvement in clinical outcome remains to be shown.


Subject(s)
ATP Binding Cassette Transporter, Subfamily B, Member 1/metabolism , ATP-Binding Cassette Transporters/metabolism , Drug Resistance, Multiple/physiology , Leukemia/drug therapy , Leukemia/metabolism , ATP Binding Cassette Transporter, Subfamily B, Member 1/genetics , ATP-Binding Cassette Transporters/genetics , Clinical Trials as Topic , Humans , Leukemia/genetics , Multidrug Resistance-Associated Proteins
11.
Leukemia ; 10 Suppl 3: S10-S17, 1996 Jul.
Article in English | MEDLINE | ID: mdl-8656694

ABSTRACT

Drug resistance is a major reason for the failure of anticancer chemotherapy. Multidrug resistance has been recognized as an important type of resistance and can be due to various mechanisms. Here we review the published data on the presence and clinical significance of these mechanisms in solid tumors and hematological malignancies. We also refer to new treatment strategies resulting from the knowledge of the various mechanisms of drug resistance present in malignant diseases.


Subject(s)
Drug Resistance, Multiple/genetics , Drug Resistance, Neoplasm/genetics , Neoplasms/genetics , ATP Binding Cassette Transporter, Subfamily B, Member 1/genetics , ATP-Binding Cassette Transporters/genetics , DNA Topoisomerases, Type I/genetics , Glutathione Transferase/genetics , Humans , Multidrug Resistance-Associated Proteins , Neoplasm Proteins/genetics
12.
Ann Oncol ; 6(8): 833-5, 1995 Oct.
Article in English | MEDLINE | ID: mdl-8589023

ABSTRACT

BACKGROUND: Paclitaxel (Taxol) as single agent has shown promising activity in advanced non-small-cell lung cancer (NSCLC). Because paclitaxel lends itself to combination with other anticancer drugs, we have determined the efficacy of paclitaxel combined with cisplatin in patients with advanced NSCLC in a phase II trial. PATIENTS AND METHODS: Twenty patients with NSCLC stage IIIB or IV were treated with paclitaxel (175 mg/m2) as a 3-hour infusion after standard premedication on day 1 and cisplatin (50 mg/m2 daily) on days 1 and 2. Treatment was repeated every 3 weeks. RESULTS: All 20 patients were evaluable for response and toxic effects. Partial responses were seen in 7 (35%) patients and no change in 9 (45%) patients. Major side effects included leukopenia, anemia, alopecia and dose-limiting neurotoxicity. CONCLUSIONS: Paclitaxel/cisplatin has shown good antitumor activity in patients with advanced NSCLC and should be further evaluated in this disease. Because neurotoxicity has been dose-limiting, methods for its prevention or early detection should further enhance the clinical value of this combination chemotherapy.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Carcinoma, Non-Small-Cell Lung/drug therapy , Lung Neoplasms/drug therapy , Adolescent , Adult , Aged , Antineoplastic Combined Chemotherapy Protocols/adverse effects , Carcinoma, Non-Small-Cell Lung/pathology , Cisplatin/administration & dosage , Female , Humans , Lung Neoplasms/pathology , Male , Middle Aged , Neoplasm Staging , Paclitaxel/administration & dosage , Paclitaxel/adverse effects
13.
Nephron ; 69(3): 277-80, 1995.
Article in English | MEDLINE | ID: mdl-7538632

ABSTRACT

The MDR1 gene, a multidrug resistance gene, codes for P-glycoprotein which pumps hydrophobic drugs out of the cells. Since cyclosporins also bind to P-glycoprotein and might be pumped by this transmembrane protein, we determined the expression of the MDR1 gene in the lymphocytes of 32 patients with renal transplants. MDR1 RNA expression of lymphocytes was measured by slot blot analysis and compared to the expression of drug-sensitive KB-3-1 cells and multidrug-resistant KB-8-5 cells. MDR1 RNA expression was detected in the lymphocytes of 9 (28%) patients, whereas no expression was seen in the remaining 23 patients. No association between MDR1 RNA expression and transplant function or hematological parameters was observed. However, none of the 6 patients who had transplants for more than 40 months expressed the MDR1 gene in their lymphocytes. In conclusion, expression of the MDR1 gene does occur in lymphocytes of patients with renal transplants and might reduce the immunosuppressive efficacy of cyclosporins through enhanced efflux of cyclosporins.


Subject(s)
ATP Binding Cassette Transporter, Subfamily B, Member 1/genetics , Drug Resistance, Multiple/genetics , Kidney Transplantation , Lymphocytes/physiology , ATP Binding Cassette Transporter, Subfamily B, Member 1/analysis , ATP Binding Cassette Transporter, Subfamily B, Member 1/metabolism , Adult , Aged , Cyclosporine/blood , Cyclosporine/pharmacokinetics , Cyclosporine/therapeutic use , Gene Expression , Graft Survival/physiology , Humans , Immunohistochemistry , Kidney Transplantation/pathology , Lymphocytes/chemistry , Lymphocytes/metabolism , Middle Aged , RNA/genetics
14.
J Cancer Res Clin Oncol ; 121 Suppl 3: R21-4, 1995.
Article in English | MEDLINE | ID: mdl-8698738

ABSTRACT

In order to evaluate dexverapamil as a resistance modifier in acute myeloid leukaemia, we have added dexverapamil (4 x 300 mg/d orally) to DA chemotherapy (daunorubicin, cytosine arabinoside) in six patients with acute myeloid leukaemia. Two patients (1 first and 1 second relapse) achieved complete remission and two patients (1 refractory disease, 1 third relapse) showed some improvement. One patient in first relapse died due to disease progression and one drug-refractory patient remained refractory. The peak plasma levels of dexverapamil and nordexverapamil ranged from about 600 to 4100 ng/ml and from 450 to 1130 ng/ml, respectively. Major sideeffects were hypotension and sinus bradycardia. These results show the need for further evaluation of dexverapamil as a resistance modifier in acute myeloid leukaemia.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Calcium Channel Blockers/administration & dosage , Leukemia, Myeloid, Acute/drug therapy , Verapamil/administration & dosage , ATP Binding Cassette Transporter, Subfamily B, Member 1/genetics , Adult , Aged , Antineoplastic Combined Chemotherapy Protocols/adverse effects , Drug Resistance , Female , Humans , Male , Middle Aged , Verapamil/blood
16.
Leukemia ; 8(6): 974-7, 1994 Jun.
Article in English | MEDLINE | ID: mdl-7516030

ABSTRACT

In order to further define the role of the MDR1 gene in acute myeloid leukemia (AML), we determined the association between the presence of P-glycoprotein on leukemic cells and the efficacy of therapy in patients with AML. Immunocytochemistry with monoclonal antibody C219 was performed to demonstrate the presence of P-glycoprotein. Positive staining ranged from 0 to 60% of the leukemic cells. For further analysis, patients were assigned into groups with 0-5% staining cells (group 1, n = 33) and with > 5% staining cells (group 2, n = 19). The complete remission rate of induction chemotherapy was 76% for group 1 but only 32% for group 2 (p = 0.002). The median duration of overall survival was 19 months for patients in group 1 as compared to 3 months for patients in group 2 (p = 0.007). The data indicate that P-glycoprotein expression is associated with an unfavorable prognosis in patients with AML.


Subject(s)
Carrier Proteins/physiology , Leukemia, Myeloid/physiopathology , Membrane Glycoproteins/physiology , ATP Binding Cassette Transporter, Subfamily B, Member 1 , Acute Disease , Adolescent , Adult , Aged , Aged, 80 and over , Antibodies, Monoclonal , Carrier Proteins/analysis , Carrier Proteins/genetics , Drug Resistance , Female , Humans , Immunohistochemistry , Leukemia, Myeloid/genetics , Male , Membrane Glycoproteins/analysis , Membrane Glycoproteins/genetics , Middle Aged , Prognosis , RNA/genetics
17.
Anticancer Res ; 14(3B): 1293-5, 1994.
Article in English | MEDLINE | ID: mdl-7915092

ABSTRACT

The expression of the MDR1 gene, a multidrug resistance gene, was determined in patients (N = 24) with myelodysplastic syndrome or acute myeloid leukemia evolving from it. MDR1 RNA expression of the mononuclear cells was detected in 14 (58%) patients. Among patients who had progressed to acute myeloid leukemia (sAML) (N = 14), MDR1 RNA expression was seen in 8 (57%) patients. Expression was observed in the 2 patients who had been pretreated with MDR drugs. These findings indicate that the MDR1 gene is frequently expressed in MDS or sAML and suggest that multidrug resistance might be involved in the clinical drug resistance of these diseases.


Subject(s)
Carrier Proteins/genetics , Drug Resistance/genetics , Leukemia, Myeloid, Acute/genetics , Membrane Glycoproteins/genetics , Myelodysplastic Syndromes/genetics , ATP Binding Cassette Transporter, Subfamily B, Member 1 , Adult , Aged , Aged, 80 and over , Female , Gene Expression , Humans , Leukemia, Myeloid, Acute/etiology , Male , Middle Aged
18.
Leuk Lymphoma ; 13(3-4): 333-8, 1994 Apr.
Article in English | MEDLINE | ID: mdl-7914128

ABSTRACT

In order to assess the clinical role of the MDR1 gene in chronic lymphocytic leukemia (CLL), we determined its expression in the leukemic cells of 39 patients with CLL and compared this with other clinical and laboratory parameters. MDR1 RNA expression was detected in 29 patients. MDR1 RNA transcripts were independent of age, treatment status of the patients and the clinical stage of CLL, but correlated with the white blood cell count and MDR2 RNA transcripts. Expression of the tumor suppressor gene p53 was found in 30 out of 37 patients and was associated with MDR1 RNA expression (P < 0.001). Immunocytochemistry using the monoclonal antibody C219 was performed in 38 patients, and in 28 cases, more than 5% of the leukemic cells were found to express cell surface P-glycoprotein. P-glycoprotein expression correlated with the expression of MDR1 RNA (P = 0.048).


Subject(s)
Carrier Proteins/genetics , Gene Expression Regulation, Leukemic , Leukemia, Lymphocytic, Chronic, B-Cell/genetics , Membrane Glycoproteins/genetics , ATP Binding Cassette Transporter, Subfamily B, Member 1 , Adrenal Cortex Hormones/administration & dosage , Adrenal Cortex Hormones/pharmacology , Aged , Aged, 80 and over , Antineoplastic Combined Chemotherapy Protocols/pharmacology , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Carrier Proteins/biosynthesis , Chlorambucil/administration & dosage , Chlorambucil/pharmacology , Cyclophosphamide/administration & dosage , Cyclophosphamide/analogs & derivatives , Cyclophosphamide/pharmacology , Female , Genes, p53 , Humans , Immunoenzyme Techniques , Leukemia, Lymphocytic, Chronic, B-Cell/drug therapy , Leukemia, Lymphocytic, Chronic, B-Cell/pathology , Male , Membrane Glycoproteins/biosynthesis , Middle Aged , Prednisone/administration & dosage , Prednisone/pharmacology , RNA, Messenger/biosynthesis , RNA, Messenger/genetics , RNA, Neoplasm/biosynthesis , RNA, Neoplasm/genetics , Vincristine/administration & dosage , Vincristine/pharmacology
19.
Wien Klin Wochenschr ; 106(14): 431-47, 1994.
Article in German | MEDLINE | ID: mdl-7941590

ABSTRACT

Lung cancer is the most frequent cause of death from cancer in men. In addition its prevalence among women is currently rapidly increasing. Main risk factors are smoking, exposure to asbestos and genetic factors. Current screening methods do not allow early detection and, hence, lung cancer is usually diagnosed at an advanced stage. The stage of the disease affects survival. In non-small cell lung cancer the probability of 5-year survival for patients is about 43% with stage I, 23% with stage II, 17% with stage IIIA and 2% with stage IIIB disease. Surgery plays a major role in patients with non-small cell lung cancer in stages I, II and maybe IIIA. In small cell lung cancer the probability of 5-year survival is about 10% for patients with limited disease and less than 1% for patients with extended disease. Although surgery plays a role in stage I to stage IIIA, chemotherapy remains the most important mode of therapy in small cell lung cancer. In stages I to IIIA, however, combined treatment modalities might improve outcome of the patients with small cell lung cancer.


Subject(s)
Carcinoma, Bronchogenic/therapy , Carcinoma, Non-Small-Cell Lung/therapy , Carcinoma, Small Cell/therapy , Lung Neoplasms/therapy , Carcinoma, Bronchogenic/etiology , Carcinoma, Bronchogenic/mortality , Carcinoma, Bronchogenic/pathology , Carcinoma, Non-Small-Cell Lung/etiology , Carcinoma, Non-Small-Cell Lung/mortality , Carcinoma, Non-Small-Cell Lung/pathology , Carcinoma, Small Cell/etiology , Carcinoma, Small Cell/mortality , Carcinoma, Small Cell/pathology , Combined Modality Therapy , Humans , Lung Neoplasms/etiology , Lung Neoplasms/mortality , Lung Neoplasms/pathology , Neoplasm Staging , Prognosis , Risk Factors , Survival Rate
20.
Leuk Lymphoma ; 12(1-2): 91-4, 1993 Dec.
Article in English | MEDLINE | ID: mdl-7909245

ABSTRACT

In order to confirm our initial report on the negative impact of MDR1 gene expression on the outcome of de novo acute myeloid leukemia (AML), we present an update of our prospective study with a larger number of patients and a longer duration of follow-up. At diagnosis, MDR1 RNA expression of the leukemic cells was negative in 37% and positive in 63% of the patients (N = 79). The complete remission rate of induction chemotherapy was 76% for MDR1 RNA negative and 54% for MDR1 RNA positive patients (p = 0.05). At a median observation duration of 33 months, the duration of overall survival was 19 months for the MDR1 RNA negative patients but only 8 months for the patients with MDR1 gene expression (p = 0.02). Thus the long-term data also indicate that MDR1 gene expression is an unfavourable prognostic factor in AML.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Carrier Proteins/biosynthesis , Drug Resistance/genetics , Gene Expression , Leukemia, Myeloid/drug therapy , Membrane Glycoproteins/biosynthesis , ATP Binding Cassette Transporter, Subfamily B, Member 1 , Acute Disease , Adolescent , Adult , Aged , Aged, 80 and over , Cytarabine/administration & dosage , Daunorubicin/administration & dosage , Female , Follow-Up Studies , Humans , Idarubicin/administration & dosage , Leukemia, Myeloid/genetics , Leukemia, Myeloid/mortality , Male , Middle Aged , Prognosis , RNA, Neoplasm/analysis , RNA, Neoplasm/biosynthesis , Remission Induction , Survival Rate , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...